It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SPOP, an E3 ubiquitin ligase, acts as a prostate-specific tumor suppressor with several key substrates mediating oncogenic function. However, the mechanisms underlying SPOP regulation are largely unknown. Here, we have identified G3BP1 as an interactor of SPOP and functions as a competitive inhibitor of Cul3SPOP, suggesting a distinctive mode of Cul3SPOP inactivation in prostate cancer (PCa). Transcriptomic analysis and functional studies reveal a G3BP1-SPOP ubiquitin signaling axis that promotes PCa progression through activating AR signaling. Moreover, AR directly upregulates G3BP1 transcription to further amplify G3BP1-SPOP signaling in a feed-forward manner. Our study supports a fundamental role of G3BP1 in disabling the tumor suppressive Cul3SPOP, thus defining a PCa cohort independent of SPOP mutation. Therefore, there are significantly more PCa that are defective for SPOP ubiquitin ligase than previously appreciated, and these G3BP1high PCa are more susceptible to AR-targeted therapy.
SPOP functions as a tumour suppressor in prostate cancer but how the protein is regulated is unclear. Here, the authors identify G3BP1 as a competitive inhibitor of SPOP and show that G3BP1-SPOP axis activates androgen signalling to drive tumorigenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Weill Medical College of Cornell University, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
2 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Weill Cornell Medicine, Department of Urology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
3 Weill Cornell Medicine, Department of Urology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
4 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
5 GenomeDx Bioscience, Vancouver, Canada (GRID:grid.452442.1) (ISNI:0000 0004 6018 813X)
6 Weill Medical College of Cornell University, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Englander Institute for Precision Medicine of Weill Cornell Medicine and New York-Presbyterian Hospital, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
7 Weill Medical College of Cornell University, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Englander Institute for Precision Medicine of Weill Cornell Medicine and New York-Presbyterian Hospital, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
8 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
9 Weill Medical College of Cornell University, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Weill Cornell Medicine, Department of Urology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Englander Institute for Precision Medicine of Weill Cornell Medicine and New York-Presbyterian Hospital, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); University of Bern, Department for Biomedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
10 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Weill Cornell Medicine, Department of Urology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Englander Institute for Precision Medicine of Weill Cornell Medicine and New York-Presbyterian Hospital, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)